Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral and Sublingual Psilocin vs Oral Psilocybin in Healthy Adults
NCT05317689Phase 1Active, not recruiting
- Sponsor
- University of California, San Francisco
- Start
- May 2022
- Primary completion
- Jan 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of psilocin and psilocybin in major depressive disorder (MDD) (2 arms), sponsored by University of California, San Francisco. Primary endpoints: Physiological Effects, Psychological Effects and 1 more. Started May 2022; status: active, not recruiting.
02
Drugs
psilocinpsilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05317689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05317689.